Marta Alonso-Peña

Dr. Marta Alonso-Peña

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in Journal of Hepatology
Verified
Journal Article
Closed access
MMMaria J. Monte
Maria J. Monte
MAMarta Alonso-Peña
Marta Alonso-Peña
Oscar Briz SanchezOscar Briz Sanchez
Oscar Briz Sanchez
EAElisa Herraez Aguilar
Elisa Herraez Aguilar
Carmen BerasainCarmen Berasain
Carmen Berasain
Jose MarinJose Marin
Jose Marin

10 April 2019 in Hepatology
Verified
Journal Article
Closed access
PDF file
ELElisa Lozano
Elisa Lozano
Rocio MaciasRocio Macias
Rocio Macias
MMMaria J. Monte
Maria J. Monte
MAMaitane Asensio
Maitane Asensio
SCSofia del Carmen
Sofia del Carmen
Jose MarinJose Marin
Jose Marin

4 May 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
CGCarolina Jiménez González
Carolina Jiménez González
MAMarta Alonso-Peña
Marta Alonso-Peña
PVPaula Argos Velez
Paula Argos Velez
JCJavier Crespo
Javier Crespo
PIPAULA IRUZUBIETA
PAULA IRUZUBIETA
Gut microbiota has a crucial role in the pathophysiology of metabolic-associated steatotic liver disease (MASLD), influencing various metabolic mechanisms and contributing to the development of the disease. Dietary interventions targeting gut microbiota have shown potential in modulating microbial composition and mitigating MASLD progression. In this context, the integration of multi-omics analysis and artificial intelligence (AI) in personalized nutrition offers new opportunities for tailoring dietary strategies based on individual microbiome profiles and metabolic responses. The use of chatbots and other AI-based health solutions offers a unique opportunity to democratize access to health interventions due to their low cost, accessibility, and scalability. Future research should focus on the clinical validation of AI-powered dietary strategies, integrating microbiome-based therapies and precision nutrition approaches. Establishing standardized protocols and ethical guidelines will be crucial for implementing AI in MASLD management, paving the way for a more personalized, data-driven approach to disease prevention and treatment.

20 June 2023 in Investigación y Educación en Enfermería
Verified
Journal Article
Open access
PDF file
MAMarta Alonso-Peña
Marta Alonso-Peña
CÁCarmen Álvarez Álvarez
Carmen Álvarez Álvarez
Objective. To summarize the most recent scientific evidence on the usefulness and implementation of simulation trainingprograms for health science students. Methods. A search and systematic review were conducted of the literature through the use of the PRISMA guidelines using the terms MESH Simulation AND healthcare AND Professional Training, including 42 articles. Results. The bibliometric analysis revealed that most of the studies were local in nature, that is, conducted in a single center, or in a few centers in the same region, from the English-speaking world, and using a mixed methodology with pre/post-test measurements. As for the educational aspects, most of the studies were conducted at universities or in the area of continuous education, used multidisciplinary teams as the student target, and used role-playing games as the simulation method. Also, these programs were especially successful in the acquisition of competencies, such as teamwork, communication, and trust. Conclusion. Clinical simulation is a teaching methodology implemented in the last twenty years, mainly in English-speaking countries; it utilizes techniques for its execution and assessment that have been validated in contrasted in many scientific studies, and lastly, it was also observed that it is useful for providing training on general competencies for multidisciplinary groups.

26 December 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
ÁSÁlvaro Santos-Laso
Álvaro Santos-Laso
MGMaria Gutierrez-Larrañaga
Maria Gutierrez-Larrañaga
MAMarta Alonso-Peña
Marta Alonso-Peña
JMJuan M. Medina
Juan M. Medina
PIPAULA IRUZUBIETA
PAULA IRUZUBIETA
JCJavier Crespo
Javier Crespo
Non-alcoholic fatty liver disease (NAFLD) is characterized by the excessive and detrimental accumulation of liver fat as a result of high-caloric intake and/or cellular and molecular abnormalities. The prevalence of this pathological event is increasing worldwide, and is intimately associated with obesity and type 2 diabetes mellitus, among other comorbidities. To date, only therapeutic strategies based on lifestyle changes have exhibited a beneficial impact on patients with NAFLD, but unfortunately this approach is often difficult to implement, and shows poor long-term adherence. For this reason, great efforts are being made to elucidate and integrate the underlying pathological molecular mechanism, and to identify novel and promising druggable targets for therapy. In this regard, a large number of clinical trials testing different potential compounds have been performed, albeit with no conclusive results yet. Importantly, many other clinical trials are currently underway with results expected in the near future. Here, we summarize the key aspects of NAFLD pathogenesis and therapeutic targets in this frequent disorder, highlighting the most recent advances in the field and future research directions.

1 July 2022 in Hepatology
Verified
Journal Article
Open access
MAMarta Alonso-Peña
Marta Alonso-Peña
RERicardo Espinosa‐Escudero
Ricardo Espinosa‐Escudero
EHElisa Herraez
Elisa Herraez
OBOscar Briz
Oscar Briz
MCMaria Luisa Cagigal
Maria Luisa Cagigal
Jose MarinJose Marin
Jose Marin
Background and Aims: A variant (p.Arg225Trp) of peroxisomal acyl‐CoA oxidase 2 (ACOX2), involved in bile acid (BA) side‐chain shortening, has been associated with unexplained persistent hypertransaminasemia and accumulation of C27‐BAs, mainly 3α,7α,12α‐trihydroxy‐5β‐cholestanoic acid (THCA). We aimed to investigate the prevalence of ACOX2 deficiency‐associated hypertransaminasemia (ADAH), its response to ursodeoxycholic acid (UDCA), elucidate its pathophysiological mechanism and identify other inborn errors that could cause this alteration. Methods and Results: Among 33 patients with unexplained hypertransaminasemia from 11 hospitals and 13 of their relatives, seven individuals with abnormally high C27‐BA levels (>50% of total BAs) were identified by high‐performance liquid chromatography‐mass spectrometry. The p.Arg225Trp variant was found in homozygosity (exon amplification/sequencing) in two patients and three family members. Two additional nonrelated patients were heterozygous carriers of different alleles: c.673C>T (p.Arg225Trp) and c.456_459del (p.Thr154fs). In patients with ADAH, impaired liver expression of ACOX2, but not ACOX3, was found (immunohistochemistry). Treatment with UDCA normalized aminotransferase levels. Incubation of HuH‐7 hepatoma cells with THCA, which was efficiently taken up, but not through BA transporters, increased reactive oxygen species production (flow cytometry), endoplasmic reticulum stress biomarkers (GRP78, CHOP, and XBP1‐S/XBP1‐U ratio), and BAXα expression (reverse transcription followed by quantitative polymerase chain reaction and immunoblot), whereas cell viability was decreased (tetrazolium salt‐based cell viability test). THCA‐induced cell toxicity was higher than that of major C24‐BAs and was not prevented by UDCA. Fourteen predicted ACOX2 variants were generated (site‐directed mutagenesis) and expressed in HuH‐7 cells. Functional tests to determine their ability to metabolize THCA identified six with the potential to cause ADAH. Conclusions: Dysfunctional ACOX2 has been found in several patients with unexplained hypertransaminasemia. This condition can be accurately identified by a noninvasive diagnostic strategy based on plasma BA profiling and ACOX2 sequencing. Moreover, UDCA treatment can efficiently attenuate liver damage in these patients.